These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 31229165)

  • 1. Targeting Biology in Non-Hodgkin Lymphoma.
    Narkhede M; Yazdy MS; Cheson BD
    Hematol Oncol Clin North Am; 2019 Aug; 33(4):727-738. PubMed ID: 31229165
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Noncellular Immune Therapies for Non-Hodgkin Lymphoma.
    Herrera AF
    Hematol Oncol Clin North Am; 2019 Aug; 33(4):707-725. PubMed ID: 31229164
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting indolent non-Hodgkin lymphoma.
    Leslie LA; Skarbnik AP; Bejot C; Stives S; Feldman TA; Goy AH
    Expert Rev Hematol; 2017 Apr; 10(4):299-313. PubMed ID: 28277849
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The current status and future impact of targeted therapies in non-Hodgkin lymphoma.
    Ujjani C; Cheson BD
    Expert Rev Hematol; 2013 Apr; 6(2):191-202; quiz 203. PubMed ID: 23547867
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and efficacy of polatuzumab vedotin + obinutuzumab for relapsed/refractory non-Hodgkin lymphomas: A phase IB/II study.
    Phillips T; Brunvand M; Chen AI; Essell J; Chiappella A; Diefenbach C; Cheng J; Ramies D; Hirata J; Morschhauser F; Flinn IW
    Am J Hematol; 2022 Jan; 97(1):E24-E27. PubMed ID: 34731510
    [No Abstract]   [Full Text] [Related]  

  • 6. Checkpoint Inhibitors and Other Immune Therapies for Hodgkin and Non-Hodgkin Lymphoma.
    Matsuki E; Younes A
    Curr Treat Options Oncol; 2016 Jun; 17(6):31. PubMed ID: 27193488
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Development and Integration of Antibody-Drug Conjugate in Non-Hodgkin Lymphoma.
    Mehta A; Forero-Torres A
    Curr Oncol Rep; 2015 Sep; 17(9):41. PubMed ID: 26194424
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Activating the Antitumor Immune Response in Non-Hodgkin Lymphoma Using Immune Checkpoint Inhibitors.
    Joshi M; Ansell SM
    J Immunol Res; 2020; 2020():8820377. PubMed ID: 33294467
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Innovative strategies in lymphoma therapy.
    Jäger U
    Wien Klin Wochenschr; 2003 Aug; 115(13-14):462-70. PubMed ID: 13677264
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Malignant lymphoma (Hodgkin lymphoma and non-Hodgkin lymphoma)].
    Kinoshita T
    Rinsho Ketsueki; 2012 Feb; 53(2):145-54. PubMed ID: 22450573
    [No Abstract]   [Full Text] [Related]  

  • 11. Clinical investigations in aggressive non-Hodgkin lymphoma.
    Jonathan F
    Clin Adv Hematol Oncol; 2008 Sep; 6(9):7-8. PubMed ID: 18998259
    [No Abstract]   [Full Text] [Related]  

  • 12. Development of targeted therapies for B-cell non-Hodgkin lymphoma and multiple myeloma.
    Hernandez-Ilizaliturri FJ; Gowda A; Czuczman MS
    Clin Adv Hematol Oncol; 2004 Sep; 2(9):606-18. PubMed ID: 16163245
    [TBL] [Abstract][Full Text] [Related]  

  • 13. New therapies in non-Hodgkin lymphoma.
    Novelli S; Sierra J; Briones J
    Expert Rev Anticancer Ther; 2015 Mar; 15(3):349-59. PubMed ID: 25582186
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CD20-negative relapse after (131)I-anti-CD20 therapy.
    Venugopal P; Leslie WT; O'Brien T; Gregory SA
    J Clin Oncol; 1999 Nov; 17(11):3692-3. PubMed ID: 10550173
    [No Abstract]   [Full Text] [Related]  

  • 15. Classification updates and clinical investigations in indolent non-Hodgkin lymphoma.
    Cheson BD
    Clin Adv Hematol Oncol; 2008 Sep; 6(9):4-6. PubMed ID: 18998258
    [No Abstract]   [Full Text] [Related]  

  • 16. [Is lymphoma curable with antibody therapy?].
    Leppä S; Nyman H; Karjalainen-Lindsberg ML
    Duodecim; 2009; 125(3):267-73. PubMed ID: 19341039
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Emerging treatment options for B-cell lymphomas.
    Zelenetz AD
    J Natl Compr Canc Netw; 2015 May; 13(5 Suppl):666-9. PubMed ID: 25995425
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Monoclonal Antibodies.
    Geskin LJ
    Dermatol Clin; 2015 Oct; 33(4):777-86. PubMed ID: 26433849
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Advances in targeted therapy for malignant lymphoma.
    Wang L; Qin W; Huo YJ; Li X; Shi Q; Rasko JEJ; Janin A; Zhao WL
    Signal Transduct Target Ther; 2020 Mar; 5(1):15. PubMed ID: 32296035
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The evolving role of targeted drugs in the treatment of Hodgkin lymphoma.
    Eichenauer DA; Engert A
    Expert Rev Hematol; 2017 Sep; 10(9):775-782. PubMed ID: 28665214
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.